Aufklappen
Schliessen
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| 07.03. | Oxurion NV reports FY results | 1 | Seeking Alpha | |
► Artikel lesen | ||||
| 07.03. | Oxurion NV Business Update - FY 2018 | 7 | GlobeNewswire (Europe) | |
| Significant Progress with Novel Diabetic Eye Disease Portfolio
Positive Topline Results from Phase 1/2 evaluating THR-317 for treatment of DME
Multiple Clinical Readouts Expected towards... ► Artikel lesen | ||||
| 28.02. | Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting | 2 | GlobeNewswire (Europe) | |
| Leuven, Belgium, 28 February 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients... ► Artikel lesen | ||||
| OXURION Aktien jetzt im kostenlosen Demokonto handeln! | LYNX | |||
► Artikel lesen | ||||
| 13.02. | Oxurion looks to cure diseases affecting the back of the eye | 1 | Proactive Investors | |
► Artikel lesen | ||||
| 04.02. | Oxurion NV to Present at the 2019 BIO CEO & Investor Conference | 5 | GlobeNewswire (Europe) | |
| Leuven, Belgium, 4 February 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with... ► Artikel lesen | ||||
| 19.12.18 | Oxurion NV to Present at 2019 Biotech Showcase[TM] Conference and Participate in CEO Power Breakfast Roundtable During the 37th Annual J.P. Morgan Healthcare Conference | 3 | PR Newswire | |
| LEUVEN, Belgium, December 19, 2018 /PRNewswire/ --
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with... ► Artikel lesen | ||||
| 05.11.18 | Oxurion and Beta Therapeutics to Develop New Heparanase Inhibitors for Treatment of dry AMD | 9 | PR Newswire | |
| LEUVEN, Belgium, November 5, 2018 /PRNewswire/ --
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with... ► Artikel lesen | ||||
| 29.10.18 | Oxurion NV Announces the Appointment of Adrienne Graves to Its Board of Directors | 97 | PR Newswire | |
| LEUVEN, Belgium, October 29, 2018 /PRNewswire/ --
Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics NV), a biopharmaceutical company developing innovative treatments... ► Artikel lesen | ||||
| 24.10.18 | Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting | 25 | PR Newswire | |
| LEUVEN, Belgium, October 24, 2018 /PRNewswire/ --
Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments... ► Artikel lesen | ||||
| 22.10.18 | Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project | 16 | PR Newswire | |
| LEUVEN, Belgium, October 22, 2018 /PRNewswire/ --
Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments... ► Artikel lesen | ||||
| 19.10.18 | ThromboGenics NV: Oxurion NV Business Update - Q3 2018 | 13 | GlobeNewswire (Europe) | |
| Shareholders' Approval and Launch of Oxurion NV as new Company Name
First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic... ► Artikel lesen | ||||
| 20.09.18 | ThromboGenics NV: Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) | 7 | GlobeNewswire (Europe) | |
| Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients... ► Artikel lesen | ||||
| 20.09.18 | ThromboGenics NV: Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) | 30 | GlobeNewswire (Europe) | |
| Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR), a biopharma company (formerly known as ThromboGenics) focused on developing treatments for back of the eye diseases with... ► Artikel lesen | ||||
| 17.09.18 | ThromboGenics NV: Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria | 13 | GlobeNewswire (Europe) | |
| Leuven, Belgium, 17 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients... ► Artikel lesen | ||||
| 10.09.18 | ThromboGenics NV: Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit | 31 | GlobeNewswire (Europe) | |
| Oxurion NV trading under "OXUR" on NYSE Euronext Brussels
Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation... ► Artikel lesen | ||||
| 06.09.18 | ThromboGenics NV: ThromboGenics Business Update - H1 2018 | 21 | GlobeNewswire (Europe) | |
| Press release6 September 2018Regulated Information
Positive Topline Results for Diabetic Eye Disease Portfolio
Shareholder approval for company name change to Oxurion NV
€10 million... ► Artikel lesen | ||||
| 03.09.18 | ThromboGenics NV: ThromboGenics becomes "Oxurion" | 40 | GlobeNewswire (Europe) | |
| Press release
Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders
Leuven, Belgium, 3 September 2018... ► Artikel lesen | ||||
| 19.07.18 | ThromboGenics NV: ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) | 43 | GlobeNewswire (Europe) | |
| Press release
Study results confirm safety and tolerability of THR-317 for intra-ocular use, and show improvement in visual acuity for up to 90 days after last injection
Leuven, Belgium... ► Artikel lesen | ||||
| 27.06.18 | ThromboGenics NV: ThromboGenics Plans Name Change to "Oxurion" | 69 | GlobeNewswire (Europe) | |
| To better reflect Company's activities and ambition to deliver best in class therapies for back of the eye disorders
Press release - Regulated Information
Leuven, Belgium, 27 June 2018... ► Artikel lesen | ||||
| 21.06.18 | ThromboGenics NV: ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC | 21 | GlobeNewswire (Europe) | |
| Press release
Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| BAYER | 57,58 | -2,90 % | Bayer-Aktie kurz vor Zusammenbruch: Neue Hiobsbotschaft aus den USA | |
| Die Aktie des Leverkusener Pharma- und Agrarchemiekonzerns Bayer findet keinen Halt. Seit der Urteilsverkündung im Verfahren des 70-jährigen Edwin Hardeman hat die Aktie des DAX-Unternehmens über 13... ► Artikel lesen | ||||
| NOVARTIS | 82,46 | -0,60 % | Novartis bringt Alcon an die Börse | |
| Wichtige Voraussetzungen für die Notiz der Tochter seien nun erfüllt, erklärte das Schweizer Unternehmen. Im Zuge der Transaktion sollen die Aktionäre damit für fünf Novartis-Aktien jeweils eine Alcon-Aktie... ► Artikel lesen | ||||
| NOVO NORDISK | 44,78 | +0,16 % | MorphoSys, Novo Nordisk, Aurora Cannabis - das rät aktuell Marion Schlegel | |
| Marion Schlegel vom Anlegermagazin DER AKTIONÄR blickt in dieser Sendung auf die aktuellen Entwicklungen in der Pharma- und Biotechbranche.Heute geht es um MorphoSys, Novo Nordisk und Aurora Cannabis.... ► Artikel lesen | ||||
| MERCK KGAA | 98,58 | -0,10 % | Merck: Ein Jahr der heeren Versprechungen | |
| von Birgit Haas, Euro am SonntagZur diesjährigen Bilanzpressekonferenz von Merck in der Konzernzentrale in Darmstadt waren Gäste aus dem Technologiezentrum in der chinesischen Freihandelszone Schanghai... ► Artikel lesen | ||||
| PFIZER | 36,96 | -0,83 % | Pfizer erwirbt Kaufoption für Vivet über 560 Mio Euro | |
| Von Tomi Kilgore
NEW YORK (Dow Jones)--Der Pharmakonzern Pfizer verstärkt sich mit einem Zukauf. Wie das amerikanische Unternehmen mitteilte, hat es eine 15-prozentige Beteiligung an dem... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage